Momo Scientific

Johns Hopkins University, 2012 - $18,500

While cervical cancer has been largely eradicated in the developed world by the incorporation of regular screening and new opportunities for vaccinations, it remains a large burden in the developing world. Inadequate healthcare infrastructure, high costs, and the lack of an appropriate technology for treatment combine to make cervical cancer the third most common cancer in the world, with over 250,000 deaths per year. Eighty-eight percent of all cases occur in the developing world.

This team, incorporated as Momo Scientific, is looking to reduce the incidence of cervical cancer in the developing world with a device called the CryoPop. The CryoPop is a patent-pending, low-cost medical device that uses dry ice for the treatment of cervical pre-cancerous lesions in low-resource settings. The device, which relies only on the carbon dioxide tanks already available in developing countries (as a result of the presence of soda companies), is ten times cheaper, thirty times more efficient, and more effective and reliable than current technology.